Key Points
- Insider selling: Director Peter Farrell sold 2,000 shares on Jan. 7 at an average of $248.83 for ~$497,660 (a 2.91% drop in his stake), and CEO Michael J. Farrell also disclosed a sale of 4,991 shares at about $248.46.
- ResMed recently beat quarterly estimates (EPS $2.55 vs. $2.49; revenue $1.34B, +9.1% YoY), has a market cap of ~$36.8B, a 1.0% dividend yield, and analyst consensus is a Moderate Buy with an average target around $296 ahead of Q2 FY2026 earnings on Jan. 29, 2026.
ResMed Inc. (NYSE:RMD - Get Free Report) Director Peter Farrell sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $248.83, for a total transaction of $497,660.00. Following the completion of the sale, the director owned 66,773 shares in the company, valued at approximately $16,615,125.59. The trade was a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
ResMed Price Performance
RMD stock opened at $252.47 on Friday. The stock has a market cap of $36.84 billion, a price-to-earnings ratio of 25.84, a P/E/G ratio of 1.69 and a beta of 0.88. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.89 and a quick ratio of 2.13. The company has a 50 day simple moving average of $248.44 and a 200 day simple moving average of $263.16. ResMed Inc. has a 1 year low of $199.92 and a 1 year high of $293.81.
ResMed (NYSE:RMD - Get Free Report) last posted its earnings results on Friday, October 31st. The medical equipment provider reported $2.55 earnings per share for the quarter, topping analysts' consensus estimates of $2.49 by $0.06. The firm had revenue of $1.34 billion for the quarter, compared to analysts' expectations of $1.33 billion. ResMed had a net margin of 27.35% and a return on equity of 25.45%. The company's revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.20 earnings per share. Research analysts anticipate that ResMed Inc. will post 9.47 EPS for the current fiscal year.
ResMed Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Thursday, November 13th were given a dividend of $0.60 per share. The ex-dividend date was Thursday, November 13th. This represents a $2.40 dividend on an annualized basis and a yield of 1.0%. ResMed's payout ratio is currently 24.56%.
Hedge Funds Weigh In On ResMed
Hedge funds have recently bought and sold shares of the company. Norges Bank bought a new stake in ResMed during the second quarter valued at $306,452,000. First Trust Advisors LP boosted its position in shares of ResMed by 285.1% during the 3rd quarter. First Trust Advisors LP now owns 445,198 shares of the medical equipment provider's stock valued at $121,864,000 after purchasing an additional 329,588 shares in the last quarter. Swedbank AB grew its stake in ResMed by 445.1% during the first quarter. Swedbank AB now owns 397,319 shares of the medical equipment provider's stock worth $88,940,000 after purchasing an additional 324,428 shares during the period. Marshall Wace LLP grew its stake in ResMed by 2,373.1% during the third quarter. Marshall Wace LLP now owns 310,987 shares of the medical equipment provider's stock worth $85,126,000 after purchasing an additional 298,412 shares during the period. Finally, Nordea Investment Management AB increased its holdings in ResMed by 37.2% in the fourth quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider's stock worth $262,027,000 after purchasing an additional 294,124 shares in the last quarter. Institutional investors own 54.98% of the company's stock.
More ResMed News
Here are the key news stories impacting ResMed this week:
- Positive Sentiment: Zacks Research raised multiple near‑term and multi‑year EPS forecasts for RMD, including modest bumps to Q1/Q2 2028 and FY2026–FY2028 (FY2026 to $10.62, FY2027 to $11.20 and FY2028 to $12.80). The upgrades signal analyst confidence in continued revenue and margin momentum, supporting upside to the stock.
- Neutral Sentiment: ResMed set its Q2 FY2026 earnings release for January 29, 2026 (after the NYSE close); management will host a webcast. This is a near‑term catalyst that could amplify moves depending on results and guidance. Earnings Date
- Neutral Sentiment: Recent coverage and commentary (Zacks pieces and other analyst notes) highlight ResMed as a growth name with rising device demand and expanding international sales; these narratives underpin investor interest but note macro risks.
- Neutral Sentiment: Analyst consensus remains constructive overall (MarketBeat shows a "Moderate Buy" consensus and an average target around ~$296), which can sustain buying interest into the earnings catalyst.
- Negative Sentiment: Insider selling by senior management: CEO Michael J. Farrell sold 4,991 shares at an average ~$248.46 and director Peter C. Farrell sold 2,000 shares at ~$248.83. While both retain large holdings, these disclosed sales can create short‑term nervousness about insider conviction. CEO Form 4
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the company. KeyCorp upped their price objective on ResMed from $298.00 to $299.00 and gave the company an "overweight" rating in a research note on Friday, October 31st. Wells Fargo & Company assumed coverage on shares of ResMed in a research report on Monday, October 13th. They issued an "equal weight" rating and a $280.00 price target for the company. UBS Group reaffirmed a "buy" rating and set a $345.00 price target on shares of ResMed in a research note on Friday, December 12th. Morgan Stanley set a $305.00 price objective on shares of ResMed in a research note on Friday, October 31st. Finally, Stifel Nicolaus decreased their price objective on ResMed from $270.00 to $260.00 and set a "hold" rating for the company in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat, ResMed currently has an average rating of "Moderate Buy" and a consensus price target of $296.09.
View Our Latest Analysis on RMD
About ResMed
(
Get Free Report)
ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.
ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
